Fresenius Medical Care plans to sell select assets of Spectra Laboratories to Quest Diagnostics as it exits non-core markets.

Quest Diagnostics Incorporated ( NYSE ... a leading provider of renal-specific laboratory testing services in the U.S. Despite a significant net loss, GRAIL Inc (GRAL) reports strong revenue ...

Fresenius Medical Care announced today that it agreed to sell select assets of its laboratory testing services to Quest ...

Quest Diagnostics DGX has achieved impressive growth over the past year, with its shares rising 38%. It has outperformed the industry’s 7.7% rise and the S&P 500 composite’s 17.1% gain. Presently ...

Quest Diagnostics will take over the kidney-focused lab testing portfolio of the dialysis giant Fresenius Medical Care—including services that Quest will then provide back to Fresenius as | The assets ...

Citi downgraded Quest Diagnostics (DGX) to Neutral from Buy with an unchanged price target of $185. The firm believes Quest is well positioned ...

Shares of Quest Diagnostics Inc. DGX slid 1.71% to $172.01 Wednesday, on what proved to be an all-around positive trading ...

Quest Diagnostics Inc. DGX benefits from its robust utilization of the Advanced Diagnostics portfolio offerings. The company also expands through strategic acquisitions, completing eight transactions ...

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic mainstream.

Presently carrying a Zacks Rank #3 (Hold), the renowned clinical laboratory continues ... natal and other germline genetic testing. Throughout 2024, Quest Diagnostics consistently generated ...